The University of Chicago Header Logo

Connection

Arlene Chapman to Magnetic Resonance Imaging

This is a "connection" page, showing publications Arlene Chapman has written about Magnetic Resonance Imaging.
Connection Strength

1.325
  1. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204.
    View in: PubMed
    Score: 0.139
  2. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep; 64(3):1035-45.
    View in: PubMed
    Score: 0.100
  3. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699.
    View in: PubMed
    Score: 0.067
  4. A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 10 06; 12(10):1695-1698.
    View in: PubMed
    Score: 0.065
  5. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216.
    View in: PubMed
    Score: 0.065
  6. Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol. 2016 11 21; 61(22):7864-7880.
    View in: PubMed
    Score: 0.062
  7. Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2016 Apr 07; 11(4):576-84.
    View in: PubMed
    Score: 0.059
  8. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015 Jul; 88(1):146-51.
    View in: PubMed
    Score: 0.056
  9. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014; 39(3):210-7.
    View in: PubMed
    Score: 0.052
  10. Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol. 2013; 38(4):333-41.
    View in: PubMed
    Score: 0.050
  11. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013 Jul; 8(7):1089-97.
    View in: PubMed
    Score: 0.048
  12. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86.
    View in: PubMed
    Score: 0.045
  13. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15.
    View in: PubMed
    Score: 0.043
  14. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol. 2011 May; 31(3):237-44.
    View in: PubMed
    Score: 0.042
  15. Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects. Magn Reson Med. 2010 Apr; 63(4):940-50.
    View in: PubMed
    Score: 0.039
  16. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb; 31(2):440-6.
    View in: PubMed
    Score: 0.039
  17. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol. 2009 Apr; 4(4):719-25.
    View in: PubMed
    Score: 0.037
  18. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):112-20.
    View in: PubMed
    Score: 0.031
  19. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62.
    View in: PubMed
    Score: 0.029
  20. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan; 1(1):64-9.
    View in: PubMed
    Score: 0.029
  21. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Dec; 64(6):2214-21.
    View in: PubMed
    Score: 0.025
  22. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342.
    View in: PubMed
    Score: 0.024
  23. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384.
    View in: PubMed
    Score: 0.022
  24. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651.
    View in: PubMed
    Score: 0.020
  25. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
    View in: PubMed
    Score: 0.019
  26. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
    View in: PubMed
    Score: 0.018
  27. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
    View in: PubMed
    Score: 0.017
  28. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865.
    View in: PubMed
    Score: 0.017
  29. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
    View in: PubMed
    Score: 0.015
  30. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72.
    View in: PubMed
    Score: 0.013
  31. Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 Feb; 9(2):406-15.
    View in: PubMed
    Score: 0.013
  32. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7.
    View in: PubMed
    Score: 0.010
  33. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18; 354(20):2122-30.
    View in: PubMed
    Score: 0.008
  34. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec; 46(6):1058-64.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.